Edition:
United States

Allied Minds PLC (ALML.L)

ALML.L on London Stock Exchange

148.20GBp
16 Feb 2018
Change (% chg)

1.20 (+0.82%)
Prev Close
147.00
Open
144.20
Day's High
149.20
Day's Low
143.60
Volume
65,768
Avg. Vol
204,916
52-wk High
426.90
52-wk Low
114.00

Chart for

About

Allied Minds PLC (Allied Minds) is an intellectual property (IP) commercialization company. The Company is focused on venture creation within the life science and technology sectors. With extensive access to hundreds of university and federal laboratories across the United States, Allied Minds forms, funds, and operates a... (more)

Overall

Beta: 2.19
Market Cap(Mil.): £354.28
Shares Outstanding(Mil.): 239.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 39.79 17.27
EPS (TTM): -- -- --
ROI: -- 5.66 35.43
ROE: -- 9.44 17.10

BRIEF-Allied Minds Announces ‍Positive Top-Line Results Of Phase 1/2 Study Of Sf0166 Eye Drops

* ‍POSITIVE TOP-LINE RESULTS OF PHASE 1/2 STUDY OF SF0166 EYE DROPS TO TREAT WET AGE-RELATED MACULAR DEGENERATION​ Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Dec 18 2017

Short seller Kerrisdale targets Woodford-backed Prothena

LONDON Hedge fund Kerrisdale Capital has taken a short position in drugmaker Prothena , a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

Nov 09 2017

UPDATE 1-Short seller Kerrisdale targets Woodford-backed Prothena

* Prothena shares drop 9 percent (Updates with latest share price)

Nov 08 2017

Woodford-backed Prothena targeted by short seller Kerrisdale

LONDON, Nov 8 Hedge fund Kerrisdale Capital has taken a short position on drugmaker Prothena, a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

Nov 08 2017

BRIEF-Allied Minds announces SciFluor SF0166 study positive top-line results

* ‍PRIMARY OUTCOME MEASURE OF SAFETY ACHIEVED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS OBSERVED IN STUDY

Sep 28 2017

Earnings vs. Estimates